Assignee
FATE THERAPEUTICS INC
US·46 granted patents·47 pending applications·211 citations·filing 2012–2025
Top patents by PatentIndex Score
93 records- 0198US10947505B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·8 cites·20 claims
- 0297US11365394B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Jun 21, 2022·14 cites·20 claims
- 0397US11162076B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Nov 2, 2021·7 cites·29 claims
- 0497US11162075B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Nov 2, 2021·5 cites·10 claims
- 0597US10626372B1Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2016·Granted Apr 21, 2020·21 cites·16 claims
- 0696US10927346B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·17 cites·22 claims
- 0796US10858628B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2016·Granted Dec 8, 2020·15 cites·25 claims
- 0896US10287606B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2017·Granted May 14, 2019·28 cites·24 claims
- 0996US10023879B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2015·Granted Jul 17, 2018·13 cites·23 claims
- 1095US11072781B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·18 cites·18 claims
- 1195US10954529B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2018·Granted Mar 23, 2021·8 cites·15 claims
- 1294US10844356B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2017·Granted Nov 24, 2020·7 cites·20 claims
- 1391US11634688B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·2 cites·11 claims
- 1490US2026035664A1Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1589US11413309B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 16, 2022·4 cites·26 claims
- 1689US11096964B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 24, 2021·4 cites·31 claims
- 1789US10851412B2Cell potency assay for therapeutic potentialFATE THERAPEUTICS INC·Filed 2014·Granted Dec 1, 2020·5 cites·20 claims
- 1889US9452186B2Enhanced stem cell compositionFATE THERAPEUTICS INC·Filed 2012·Granted Sep 27, 2016·13 cites·40 claims
- 1987US11352607B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·2 cites·28 claims
- 2087US11268069B2Reprogramming methods and cell culture platformsFATE THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2022·4 cites·13 claims
- 2187US2026035672A1Cell culture platform for single cell sorting and enhanced reprogramming of ipscsFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2287US2026062676A1Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2385US12385012B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2023·Granted Aug 12, 2025·0 cites·15 claims
- 2483US11932870B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2024·2 cites·14 claims
- 2582US11441126B2Platform for the induction and maintenance of ground state pluripotencyFATE THERAPEUTICS INC·Filed 2016·Granted Sep 13, 2022·2 cites·21 claims
- 2679US2026091382A1Adjustable grip support for handheld pipetteFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2778US12410403B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Sep 9, 2025·0 cites·20 claims
- 2878US10111907B2Methods of treating ischemiaFATE THERAPEUTICS INC·Filed 2012·Granted Oct 30, 2018·4 cites·12 claims
- 2978US9943545B2Stem cell culture media and methods of enhancing cell survivalFATE THERAPEUTICS INC·Filed 2014·Granted Apr 17, 2018·2 cites·55 claims
- 3076US2025032547A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3175US12203098B2Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Granted Jan 21, 2025·0 cites·30 claims
- 3275US12173274B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Dec 24, 2024·0 cites·22 claims
- 3374US12264322B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2021·Granted Apr 1, 2025·0 cites·23 claims
- 3474US10980838B2Methods of treating ischemiaFATE THERAPEUTICS INC·Filed 2018·Granted Apr 20, 2021·1 cites·16 claims
- 3573US12419870B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2022·Granted Sep 23, 2025·0 cites·16 claims
- 3673US12415989B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2020·Granted Sep 16, 2025·0 cites·11 claims
- 3773US12398373B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2018·Granted Aug 26, 2025·0 cites·26 claims
- 3873US12122846B2Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·16 claims
- 3973US2025145966A1Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4073US2022118021A1Enhanced stem cell compositionFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4172US12351831B2Platform for the induction and maintenance of ground state pluripotencyFATE THERAPEUTICS INC·Filed 2022·Granted Jul 8, 2025·0 cites·20 claims
- 4272US12281329B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2021·Granted Apr 22, 2025·0 cites·27 claims
- 4372US2021324340A1Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4472US2025228943A1Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4572US2024263135A1Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4671US11052118B2Enhanced stem cell compositionFATE THERAPEUTICS INC·Filed 2018·Granted Jul 6, 2021·0 cites·16 claims
- 4770US2025215396A1Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4870US2025222029A1Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4969US12275955B2Combining iPSC derived effector cell types for immunotherapy useFATE THERAPEUTICS INC·Filed 2021·Granted Apr 15, 2025·0 cites·40 claims
- 5069US2025000904A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when FATE THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →